NCT03188276View on ClinicalTrials.gov

The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

May 1, 2017

Study Completion Date

May 1, 2017

Conditions
Chronic Hepatitis C
Interventions
DRUG

Ledipasvir-Sofosbuvir

15 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks

DRUG

Daclatasvir-Sofosbuvir

17 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.

All Listed Sponsors
lead

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT03188276 - The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs | Biotech Hunter | Biotech Hunter